What is Immunome's deferred revenue?

Immunome (IMNM) reported deferred revenue of $0 in Q4 2025.

How has Immunome's deferred revenue changed year-over-year?

Immunome's deferred revenue decreased by 100.0% year-over-year, from $6.94M to $0.

What is the long-term trend for Immunome's deferred revenue?

Over 2 years (2023 to 2025), Immunome's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $10.49M to $0.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Immunome IMNM Deferred Revenue

Deferred Revenue at other companies

Arcus BiosciencesRCUS

$34M-52.8%

Nuvation BioNUVB

$8.65M-19.7%

IDEAYA Biosciences, Inc.IDYA

$490K—

Adaptive BiotechnologiesADPT

$49.4M-9.9%

CRISPR TherapeuticsCRSP

$15.34M+408%

ExelixisEXEL

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Immunome’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's deferred revenue?: Immunome (IMNM) reported deferred revenue of $0 in Q4 2025.
How has Immunome's deferred revenue changed year-over-year?: Immunome's deferred revenue decreased by 100.0% year-over-year, from $6.94M to $0.
What is the long-term trend for Immunome's deferred revenue?: Over 2 years (2023 to 2025), Immunome's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $10.49M to $0.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.